GENFIT Secures US$20M Milestone with Iqirvo® Success

GENFIT, a biopharmaceutical firm, has announced a milestone payment of US$20 million from Ipsen following Iqirvo®'s successful debut year on the market for Primary Biliary Cholangitis (PBC), with net sales reaching US$208 million. This marks a significant triumph for GENFIT, enhancing its financial stability and unlocking an additional €30 million under a royalty-financing agreement.

Beyond financial achievements, Ipsen is set to launch a global Phase 3 trial for primary sclerosing cholangitis (PSC), a condition with no existing approved treatments. A future regulatory nod could result in more payments and royalties for GENFIT. Concurrently, GENFIT progresses in its oncology ventures, including a Phase 1b study on cholangiocarcinoma, showing promising early results.

These developments underline GENFIT's commitment to addressing unmet medical needs, with 2026 poised as a pivotal year for the company.